TScan Therapeutics (NASDAQ:TCRX) Given New $5.00 Price Target at Wedbush

TScan Therapeutics (NASDAQ:TCRX) had its price target lifted by Wedbush from $4.00 to $5.00 in a report released on Thursday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

TCRX has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a report on Thursday, January 22nd. Morgan Stanley cut shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Finally, HC Wainwright decreased their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.20.

TScan Therapeutics Stock Up 4.6%

Shares of TCRX stock opened at $1.13 on Thursday. TScan Therapeutics has a 52-week low of $0.88 and a 52-week high of $2.57. The stock has a market cap of $64.13 million, a price-to-earnings ratio of -1.13 and a beta of 1.03. The firm’s 50-day moving average is $1.06 and its 200-day moving average is $1.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. The firm had revenue of $2.57 million for the quarter. TScan Therapeutics had a negative return on equity of 73.32% and a negative net margin of 1,256.81%. Sell-side analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Transactions at TScan Therapeutics

In other news, major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average cost of $0.90 per share, with a total value of $67,950.00. Following the acquisition, the insider directly owned 8,012,916 shares in the company, valued at $7,211,624.40. This represents a 0.95% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders acquired 161,801 shares of company stock valued at $145,621. Insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors have recently modified their holdings of the business. Catalyst Funds Management Pty Ltd bought a new position in TScan Therapeutics during the second quarter worth about $26,000. Quadrature Capital Ltd bought a new stake in TScan Therapeutics in the 2nd quarter valued at about $33,000. Boothbay Fund Management LLC grew its position in shares of TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares in the last quarter. Panagora Asset Management Inc. bought a new position in shares of TScan Therapeutics during the fourth quarter worth approximately $25,000. Finally, HRT Financial LP bought a new position in shares of TScan Therapeutics during the fourth quarter worth approximately $26,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.